Search Results 901-910 of 21561 for Inhibition

  1. Chemotherapy For Clinical Trials - Mayo Clinic Research

    ... inhibitor work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the ...

  2. Medicines called angiotensin-converting enzyme inhibitors, also known as ACE inhibitors; Neuromuscular diseases that weaken the coordination of upper airway ...

  3. Coagulation factor ix recombinant, glycopegylated (intravenous route) - Side effects & uses - Mayo Clinic

    Patients with factor IX inhibitors—May increased risk of having an allergic reaction. Back to top. Proper Use. A doctor or other trained health professional ...

  4. Golden Calf Trial - Mayo Clinic

    Concomitant use of strong CYP3A4 inhibitors (e.g., HIV protease inhibitors, systemic ketoconazole) or strong CYP 3A4 inducers like rifampicin. Active cancer ...

  5. A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination with Crizotinib - Mayo Clinic

    Prior anti-cancer treatment with any HSP90 inhibitor; Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib ...

  6. Doctors & Departments - Mayo Clinic

    Identifying an enzyme that regulates DNA repair; Identifying subsets of women who do not benefit from cancer drugs called aromatase inhibitors; Identifying ...

  7. SYMPHONY: A Study Of Macitentan In Pulmonary Arterial Hypertension To Validate The PAH-SYMPACT - Mayo Clinic

    For patients on phosphodiesterase type-5 inhibitors ... Treatment with strong cytochrome P450 (CYP) 3A4 inducers or inhibitors within 4 weeks prior to Visit 2 ...

  8. A Study of Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients with Previously Treated Multiple Myeloma or Plasma Cell Leukemia - Mayo Clinic

    Participation eligibility · strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2). fluvoxamine; enoxacin; ciprofloxacin · strong ...

  9. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

    Any prior irreversible BTK inhibitor therapy. Note: Prior treatment with reversible, noncovalent BTK inhibitors is not excluded on this protocol. Prior ...

  10. Dabrafenib (oral route) - Side effects & dosage - Mayo Clinic

    Description. Dabrafenib is used alone or in combination with trametinib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery ...